Foxy-5

DRUG3 trials

Sponsors

WntResearch AB

Conditions

Colon CancerColorectal CancerMetastatic Breast CancerMetastatic Colon CancerMetastatic Prostate CancerProstate Cancer

Phase 1

Phase I Study to Evaluate Safety, Tolerability, Anti-Tumour Activity and PK Profiles of Foxy-5 in Metastatic Breast, Colon or Prostate Cancer

CompletedNCT02020291

WntResearch ABColorectal Cancer, Metastatic Breast Cancer, Prostate Cancer

Start: 2013-06-30End: 2015-11-30Updated: 2016-02-02

Dose Escalating Study of Foxy-5 in Breast-, Colon- or Prostate Cancer Patients

CompletedNCT02655952

WntResearch ABMetastatic Breast Cancer, Metastatic Colon Cancer, Metastatic Prostate Cancer

Start: 2016-04-30End: 2017-10-31Updated: 2018-12-28

Phase 2

Foxy-5 as Neo-Adjuvant Therapy in Subjects With Wnt-5a Low Colon Cancer

WntResearch ABColon Cancer

Start: 2019-04-12End: 2024-12-14Target: 100Updated: 2022-12-09

Related Papers

Abstract A116: Targeting the Wnt-5a signaling pathway as a novel anti-metastatic therapy

Molecular Cancer Therapeutics2015-12-018 citations

Phase I dose-escalating study to evaluate the safety, tolerability, and pharmacokinetic and pharmacodynamic profiles of Foxy-5 in patients with metastatic breast, colorectal, or prostate cancer.

Journal of Clinical Oncology2014-05-2011 citations